Clinical Study

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1A

Posted Date: May 15, 2019

  • Investigator: Joseph Nicolas
  • Specialties:
  • Type of Study: Drug

This study is being conducted by F. Hoffmann-La Roche Ltd. (Roche) and Genentech Inc, called ?Sponsor? later on in this document. We want to confirm whether patients treated with ocrelizumab may experience even fewer clinical relapses (also called clinical attacks or exacerbations) compared with th

Criteria:

? You Must Be 18 To 55 Years Of Age. ? You Must Pass The Screening Medical Examinations And Tests (

Keywords:

Relapsing-Remitting, Opera, Ocrelizumab, Multiple Sclerosis

For More Information:

Alecia Boehl
513-558-0039
alecia.boehl@uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.